Medical Crossfire®: Global Perspectives on Recent Data in Hormone Receptor-Positive Breast Cancer: Individualizing and Optimizing Use of CDK4/6 Inhibitors

Release Date: January 15, 2021
Expiration Date: January 15, 2022

Activity Overview

This online, on-demand virtual symposium brings together 5 key thought leaders to discuss the role of CDK4/6 inhibitors in the management of patients with hormone receptor-positive (HR+) breast cancer. In this educational program, experts cover evolving evidence in the metastatic setting as well as strategies for individualizing and optimizing treatment. In addition, they review emerging data in the setting of early-stage breast cancer and discuss how recent results will impact the management of patients with high-risk disease. This lively discussion will help place new developments into clinical context to help optimize care for patients with HR+ breast cancer.

This educational activity is an archive of the live virtual symposium held on December 14, 2020.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Lilly.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with breast cancer. Other physicians, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Review recent results from pivotal clinical trials evaluating CDK4/6 inhibitors for the treatment of patients with HR+ breast cancer and the impact of these data on treatment decision-making
• Utilize tumor and patient characteristics when incorporating CDK4/6 inhibitors in order to individualize treatment strategies and optimize outcomes for patients with HR+ metastatic breast cancer (MBC)
• Integrate predictive and prognostic assays to assess risk of recurrence in patients with early-stage HR+ breast cancer and to identify patients eligible for clinical trials evaluating novel combinations of endocrine therapies and targeted agents
• Assess strategies to optimize treatment protocols for patients with HR+ MBC in light of the current COVID-19 pandemic, and ensure adherence to therapy in patients receiving oral anticancer medications

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Fabrice André, MD, PhD
Professor, Department of Medical Oncology
Institut Gustave Roussy
Villejuif, France

Disclosures: Grant Research Support: AstraZeneca, Lilly, Novartis, Pfizer, Roche/Genentech

Stephen R. D. Johnston, MA, PhD, FRCP
Professor of Breast Cancer Medicine & Head of Medical Oncology
Consultant Medical Oncologist & Head of The Breast Unit
The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research
London, United Kingdom

Disclosures: Grant Research Support: AstraZeneca, Lilly, Novartis, Pfizer, Puma Biotechnology, Roche/Genentech; Consultant: AstraZeneca, Lilly, Novartis, Pfizer, Puma Biotechnology; Speakers Bureau: AstraZeneca, Eisai, Novartis, Pfizer, Roche/Genentech

George W. Sledge Jr., MD
Professor of Medicine (Oncology)
Stanford University Medical Center
Palo Alto, CA

Disclosures: Grant Research Support: Genentech, Pfizer, QED Therapeutics; Consultant: Lilly, Verseau Therapeutics; Other: Member, Board of Directors: Tessa

Sara M. Tolaney, MD, MPH
Associate Director, Susan F. Smith Center for Women’s Cancers
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Senior Physician, Breast Oncology Program
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Consultant: AstraZeneca, Lilly, Merck, Nektar Therapeutics, Novartis, Pfizer, Bristol Myers Squibb, Eisai, NanoString Technologies, Cyclacel Pharmaceuticals, Sanofi, Odonate Therapeutics, Seagen, Daiichi Sankyo, AbbVie, Athenex Oncology, OncoPep; Other: AstraZeneca, Lilly, Merck, Nektar Therapeutics, Novartis, Pfizer, Immunomedics, Exelixis, Bristol Myers Squibb, Eisai, NanoString Technologies, Puma Biotechnology, Sanofi, Celldex Therapeutics, Odonate Therapeutics, Silver Therapeutics, G1 Therapeutics, Kyowa Kirin, Samsung Bioepis, CytomX Therapeutics, Gilead Sciences, Certara, Mersana Therapeutics

Nicholas Turner, MD, PhD
Consultant Medical Oncologist
Head, Ralph Lauren Centre for Breast Cancer Research
Team Leader, Molecular Oncology, Breast Cancer Now Toby Robins Research Centre
Breast Theme Lead, The Royal Marsden NIHR Biomedical Research Centre
Professor of Molecular Oncology
Institute of Cancer Research
London, United Kingdom

Disclosures: Grant Research Support: AstraZeneca, Bio-Rad Laboratories, Guardant Health, Puma Biotechnology; Consultant: AstraZeneca, Puma Biotechnology

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.